[Articles] Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentr
In people with type 2 diabetes, once-weekly subcutaneous zenagamtide 0·4–40 mg demonstrated clinically meaningful and significant improvements in change in HbA1c from baseline to week 36 compared with placebo, with a safety and tolerability profile consistent with that of other G
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.